These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26387750)

  • 1. 16th World Conference on Lung Cancer.
    Landman A
    Lancet Oncol; 2015 Oct; 16(13):1290. PubMed ID: 26387750
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.
    Wallerek S; Sørensen JB
    Eur Respir Rev; 2015 Jun; 24(136):340-55. PubMed ID: 26028645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
    Haddad FG; Kourie HR; Kattan J
    Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
    Gadgeel SM
    Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
    [No Abstract]   [Full Text] [Related]  

  • 6. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
    Wijesinghe P; Bollig-Fischer A
    Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
    World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Treatment Options for Lung Cancer.
    Morgensztern D; Herbst RS
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):xiii-xiv. PubMed ID: 27912837
    [No Abstract]   [Full Text] [Related]  

  • 10. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L; Zhang H; Shao W; Chen B
    Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.
    Chuang JC; Liang Y; Wakelee HA
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):31-44. PubMed ID: 27912832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.
    Stinchcombe TE
    Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    López-Brea M
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant chemotherapy benefits older and younger non-small cell lung cancer patients alike.
    Barton MK
    CA Cancer J Clin; 2012; 62(5):279-80. PubMed ID: 22847502
    [No Abstract]   [Full Text] [Related]  

  • 15. Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer.
    Van Schil PE
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):718; author reply 718-9. PubMed ID: 18329516
    [No Abstract]   [Full Text] [Related]  

  • 16. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant chemotherapy after pulmonary resection for lung cancer.
    Mascaux C; Shepherd FA
    Thorac Surg Clin; 2013 Aug; 23(3):401-10. PubMed ID: 23931022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
    Zhang C; Li J; Han Y; Jiang J
    Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should "RET positive" NSCLC be treated?
    Smit EF
    Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
    [No Abstract]   [Full Text] [Related]  

  • 20. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.